• 1
    Balch CM, Buzaid AC, Soong SJ et al. Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol. 2001; 19: 3635-3648.
  • 2
    Balch CM, Soong SJ, Gershenwald JE, et al. Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. J Clin Oncol. 2001; 19: 3622-3634.
  • 3
    Balch CM, Gershenwald JE, Soong SJ, et al. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol. 2009; 27: 6199-6206.
  • 4
    Balch CM, Soong SJ, Milton GW, et al. A comparison of prognostic factors and surgical results in 1,786 patients with localized (stage I) melanoma treated in Alabama, USA, and New South Wales, Australia. Ann Surg. 1982; 196: 677-684.
  • 5
    Balch CM, Wilkerson JA, Murad TM, et al. The prognostic significance of ulceration of cutaneous melanoma. Cancer. 1980; 45: 3012-3017.
  • 6
    Francken AB, Shaw HM, Thompson JF, et al. The prognostic importance of tumor mitotic rate confirmed in 1317 patients with primary cutaneous melanoma and long follow-up. Ann Surg Oncol. 2004; 11: 426-433.
  • 7
    Azzola MF, Shaw HM, Thompson JF, et al. Tumor mitotic rate is a more powerful prognostic indicator than ulceration in patients with primary cutaneous melanoma: an analysis of 3661 patients from a single center. Cancer. 2003; 97: 1488-1498.
  • 8
    Oken MM, Creech RH, Tormey DC, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 1982; 5: 649-655.
  • 9
    Eton O, Legha SS, Moon TE, et al. Prognostic factors for survival of patients treated systemically for disseminated melanoma. J Clin Oncol. 1998; 16: 1103-1111.
  • 10
    Bower MR, Scoggins CR, Martin RC 2nd, et al. Second primary melanomas: incidence and outcome. Am Surg. 2010; 76: 675-681.
  • 11
    Burden AD, Vestey JP, Sirel JM, et al. Multiple primary melanoma: risk factors and prognostic implications. BMJ. 1994; 309: 375.
  • 12
    Doubrovsky A, Menzies SW. Enhanced survival in patients with multiple primary melanoma. Arch Dermatol. 2003; 139: 1013-1018.
  • 13
    Orlow I, Tommasi DV, Bloom B, et al. Evaluation of the clonal origin of multiple primary melanomas using molecular profiling. J Invest Dermatol. 2009; 129: 1972-1982.
  • 14
    Mann GJ, Pupo GM, Campain AE, et al. BRAF mutation, NRAS mutation and absence of an immune-related expressed gene profile predict poor outcome in surgically resected stage III melanoma. Pigment Cell Melanoma Res. 2010; 23: 874-1004.
  • 15
    Guerriere-Kovach PM, Hunt EL, Patterson JW, et al. Primary melanoma of the skin and cutaneous melanomatous metastases: comparative histologic features and immunophenotypes. Am J Clin Pathol. 2004; 122: 70-77.
  • 16
    Agarwala SS, Keilholz U, Gilles E, et al. LDH correlation with survival in advanced melanoma from 2 large, randomised trials (Oblimersen GM301 and EORTC 18951). Eur J Cancer. 2009; 45: 1807-1814.
  • 17
    Khan MA, Andrews S, Ismail-Khan R, et al. Overall and progression-free survival in metastatic melanoma: analysis of a single-institution database. Cancer Control. 2006; 13: 211-217.
  • 18
    Manola J, Atkins M, Ibrahim J, Kirkwood J. Prognostic factors in metastatic melanoma: a pooled analysis of Eastern Cooperative Oncology Group trials. J Clin Oncol. 2000; 18: 3782-3793.
  • 19
    Long GV, Menzies AM, Nagrial AM, et al. Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma. J Clin Oncol. 2011; 29: 1239-1246.